Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in 143 Phase III Trials
Authors:
Open Access
- 1 May 2007
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 2 (5) , 402-407
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer PatientsJournal of Clinical Oncology, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599Journal of Clinical Oncology, 2005
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003Journal of Clinical Oncology, 2004
- Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A ReviewJournal of Clinical Oncology, 2000
- Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysisThe Lancet, 2000
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy RegimensJournal of Clinical Oncology, 2000
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancerAnnals of Oncology, 1998